Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) Debt to Equity (2016 - 2024)

Capricor Therapeutics has reported Debt to Equity over the past 14 years, most recently at $0.05 for Q3 2024.

  • Quarterly results put Debt to Equity at $0.05 for Q3 2024, up 102.62% from a year ago — trailing twelve months through Sep 2024 was $0.05 (up 102.62% YoY), and the annual figure for FY2023 was $0.15, down 49.2%.
  • Debt to Equity for Q3 2024 was $0.05 at Capricor Therapeutics, down from $0.29 in the prior quarter.
  • Over the last five years, Debt to Equity for CAPR hit a ceiling of $1.24 in Q2 2023 and a floor of -$1.89 in Q3 2023.
  • Median Debt to Equity over the past 5 years was $0.15 (2023), compared with a mean of $0.12.
  • Biggest five-year swings in Debt to Equity: soared 16345.77% in 2022 and later crashed 941.96% in 2023.
  • Capricor Therapeutics' Debt to Equity stood at $0.12 in 2020, then increased by 5.86% to $0.13 in 2021, then surged by 131.99% to $0.29 in 2022, then plummeted by 49.2% to $0.15 in 2023, then tumbled by 66.89% to $0.05 in 2024.
  • The last three reported values for Debt to Equity were $0.05 (Q3 2024), $0.29 (Q2 2024), and $0.18 (Q1 2024) per Business Quant data.